Please try another search
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Name | Age | Since | Title |
---|---|---|---|
Andrea Small-Howard | 54 | 2014 | Chairman of Scientific Advisory Board, Chief Science Officer, President & Director |
Helen Turner | - | 2014 | Member of Scientific Advisory Board |
Norbert E. Kaminski | - | - | Member of Scientific Advisory Board |
Carlos F. Rios-Bedoya | - | - | Member of Scientific Advisory Board |
John Claybron Poss | 75 | 2015 | CEO, Interim CFO & Chairman |
Alexander Stokes | - | - | Member of Scientific Advisory Board |
Edmond A. DeFrank | 55 | 2019 | Independent Director |
Zoltan Mari | - | 2018 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review